The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls

Rationale3, 4-Methylenedioxymethamphetamine (MDMA or “ecstasy”) is a popular drug of abuse known to result in depletions of the serotonin (5-HT) system. A number of studies have reported that ecstasy users differ from controls on a variety of measures of cognitive function. However, the literature is not consistent and many negative findings were also reported. One reason for such inconsistency might be interindividual variance in vulnerability to the deleterious effects of ecstasy due to a number of factors, both genetic and environmental.ObjectivesTo investigate the hypothesis that carriers of the s allele at the 5-HT transporter gene-linked polymorphic region (5-HTTLPR), which was associated with reduced serotonergic neurotransmission relative to the l allele, would be most vulnerable to the effects of ecstasy on cognitive function.MethodsWe assessed memory, decision-making, and executive function in ecstasy users and controls, stratifying by genotype at the 5-HTTLPR.ResultsWe observed that the 5-HTTLPR genotype groups differed on a number of measures in both the ecstasy users and the controls. While performing a risky decision-making task, ss and ls controls attended to differences in the probability of winning chosen gambles to a greater extent than the ll controls. However, this difference was dramatically attenuated in the ss ecstasy users. Furthermore, independent of ecstasy use, volunteers of the ss genotype outperformed the ll genotype on a visual planning task.ConclusionsThe results are consistent with the hypothesis that cognitive impairment in ecstasy users may depend on genetic variation at the 5-HTTLPR.

[1]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[2]  R. Shepard,et al.  Mental Rotation of Three-Dimensional Objects , 1971, Science.

[3]  A. Tversky,et al.  Prospect theory: analysis of decision under risk , 1979 .

[4]  A. Tversky,et al.  Prospect Theory : An Analysis of Decision under Risk Author ( s ) : , 2007 .

[5]  D. C. Howell.  Statistical Methods for Psychology , 1987 .

[6]  T. Robbins,et al.  A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. , 1988, Brain : a journal of neurology.

[7]  B. Sahakian,et al.  The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type , 1989, British Journal of Psychiatry.

[8]  Jacob Cohen.  Statistical Power Analysis , 1992 .

[9]  C. Marsden,et al.  Neurobehavioural changes in a patient with bilateral lesions of the globus pallidus. , 1993, Behavioural neurology.

[10]  Y. Shaham,et al.  Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.

[11]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[12]  U. McCann,et al.  Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.

[13]  G. Gerra,et al.  Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.

[14]  D. Easton,et al.  Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. , 1998, American journal of medical genetics.

[15]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[16]  Klaus P. Ebmeier,et al.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.

[17]  T. Robbins,et al.  Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour , 1999, Psychopharmacology.

[18]  T. Robbins,et al.  Dissociable Deficits in the Decision-Making Cognition of Chronic Amphetamine Abusers, Opiate Abusers, Patients with Focal Damage to Prefrontal Cortex, and Tryptophan-Depleted Normal Volunteers: Evidence for Monoaminergic Mechanisms , 1999, Neuropsychopharmacology.

[19]  M. Morgan.  Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.

[20]  D. Murphy,et al.  Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users , 1999, Psychopharmacology.

[21]  M. Morgan,et al.  Ecstasy (MDMA): a review of its possible persistent psychological effects , 2000, Psychopharmacology.

[22]  F. Vollenweider,et al.  3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by (H 2 15 O)-PET in , 2000 .

[23]  W J Riedel,et al.  Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers , 2000, Journal of psychopharmacology.

[24]  K. Lesch,et al.  Reduction in the Density and Expression, But Not G-Protein Coupling, of Serotonin Receptors (5-HT1A) in 5-HT Transporter Knock-Out Mice: Gender and Brain Region Differences , 2000, The Journal of Neuroscience.

[25]  Paul J. Harrison,et al.  Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine , 2000, Psychopharmacology.

[26]  W. J. Riedel,et al.  Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers , 2001, Psychopharmacology.

[27]  W. van den Brink,et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.

[28]  C Reist,et al.  Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. , 2001, American journal of medical genetics.

[29]  J. Powell,et al.  Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment , 2001, Psychological Medicine.

[30]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[31]  S. Kasper,et al.  Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. , 2002, Archives of general psychiatry.

[32]  B. Sahakian,et al.  Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.

[33]  T. Robbins,et al.  The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers , 2002, Psychopharmacology.

[34]  Peter Gallagher,et al.  Effects of acute tryptophan depletion on executive function in healthy male volunteers , 2003, BMC psychiatry.

[35]  V. Arango,et al.  Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice , 2003, Biological Psychiatry.

[36]  R. Rogers,et al.  Effects of beta-adrenoceptor blockade on components of human decision-making , 2004, Psychopharmacology.

[37]  P. Cowen,et al.  Acute administration of nutritionally sourced tryptophan increases fear recognition , 2003, Psychopharmacology.

[38]  B. Sahakian,et al.  Relationship between ecstasy use and depression: a study controlling for poly-drug use , 2004, Psychopharmacology.

[39]  P. Cowen,et al.  Tryptophan depletion decreases the recognition of fear in female volunteers , 2003, Psychopharmacology.

[40]  R. Coppola,et al.  Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. , 2003, Archives of general psychiatry.

[41]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[42]  E. Gouzoulis-Mayfrank,et al.  Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  C. Carter,et al.  Tryptophan Depletion Alters the Decision-Making of Healthy Volunteers through Altered Processing of Reward Cues , 2003, Neuropsychopharmacology.

[44]  J. Snel,et al.  Impaired executive function in male MDMA (“ecstasy”) users , 2004, Psychopharmacology.

[45]  R. Croft,et al.  Chronic MDMA (ecstasy) use, cognition and mood , 2004, Psychopharmacology.

[46]  N. Ramnani,et al.  Distinct portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward processing in separable phases of decision-making cognition , 2004, Biological Psychiatry.

[47]  David Eidelberg,et al.  Effects of Serotonin Transporter Promoter Polymorphisms on Serotonin Function , 2004, Neuropsychopharmacology.

[48]  G K L Butler,et al.  Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. , 2004, Drug and alcohol dependence.

[49]  M. Luciana,et al.  Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use , 2004, Psychological Medicine.

[50]  Ralph Buchert,et al.  A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.

[51]  Trevor R. Norman,et al.  Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women , 2004, Journal of psychopharmacology.

[52]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[53]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[54]  Sean P David,et al.  A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT1A Receptor Binding in Humans , 2005, The Journal of Neuroscience.

[55]  Christian Büchel,et al.  Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter , 2005, Nature Neuroscience.

[56]  B. Sahakian,et al.  Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. , 2005, The American journal of psychiatry.

[57]  B. Sahakian,et al.  Neuropsychological function in ecstasy users: a study controlling for polydrug use , 2006, Psychopharmacology.

[58]  Dennis L. Murphy,et al.  Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter , 2005, Neuropharmacology.

[59]  B. Schmand,et al.  Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users , 2006, Journal of psychopharmacology.

[60]  R. Rogers,et al.  Elevated Impulsivity and Impaired Decision-Making in Abstinent Ecstasy (MDMA) Users Compared to Polydrug and Drug-Naïve Controls , 2006, Neuropsychopharmacology.